Aakash Desai/LinkedIn
Jun 1, 2025, 14:41
Aakash Desai: Interim Results from Our Phase 1 Trial of PDL1V, a Vedotin-Based ADC Targeting PD-L1 in R/R NSCLC at ASCO 2025
Aakash Desai, Assistant Professor and Associate Director of Phase 1 and Precision Oncology Program at the UAB O’Neal Comprehensive Cancer Center, shared a post on LinkedIn:
“Excited to share interim results from our Phase 1 trial of PDL1V (PF-08046054), a vedotin-based ADC targeting PD-L1 in R/R NSCLC (ASCO 2025, Abstract 8611).
– 30 pts treated at RP2D
– 83.3% PD-L1+
– 96.7% prior PD-(L)1
– No DLTs
– Common TRAEs:
→ Peripheral neuropathy (27.2%)
→ Nausea (25%)
→ Diarrhea (23.9%)
→ Fatigue (21.7%)Confirmed ORR = 26.7%
→ PD-L1+ tumors: ORR = 32.0%
→ cORR: Sq = 33.3%, Non-sq = 31.6%
Median duration of response = 7.8 mo
Median f/u = 10 moGrateful to help bring novel therapies to our patients in Alabama UAB O’Neal Comprehensive Cancer Center and beyond․”
More posts featuring Aakash Desai on OncoDaily.
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Jun 26, 2025, 14:50
Jun 26, 2025, 14:20
Jun 26, 2025, 13:31